Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × perillyl alcohol × Clear all
NCT02704858 2026-03-02

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Neonc Technologies, Inc.

Phase 1/2 Recruiting
49 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡